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Abstract
Plasma membrane integrity is essential for cell life. Any major break on it immediately
induces the death of the affected cell. Different molecules were described as disrupting this
cell structure and thus showing antitumor activity. We have previously defined that elisidep-
sin (Irvalec1, PM02734) inserts and self-organizes in the plasma membrane of tumor cells,
inducing a rapid loss of membrane integrity, cell permeabilization and necrotic death. Here
we show that, in sensitive HCT-116 colorectal cells, all these effects are consequence of
the interaction of elisidepsin with glycosylceramides in the cell membrane. Of note, an elisi-
depsin-resistant subline (HCT-116-Irv) presented reduced levels of glycosylceramides and
no accumulation of elisidepsin in the plasma membrane. Consequently, drug treatment did
not induce the characteristic necrotic cell death. Furthermore, GM95, a mutant derivative
from B16 mouse melanoma cells lacking ceramide glucosyltransferase (UGCG) activity
and thus the synthesis of glycosylceramides, was also resistant to elisidepsin. Over-expres-
sion of UGCG gene in these deficient cells restored glycosylceramides synthesis, rendering
them sensitive to elisidepsin, at a similar level than parental B16 cells. These results indi-
cate that glycosylceramides act as membrane targets of elisidepsin, facilitating its insertion
in the plasma membrane and the subsequent membrane permeabilization that leads to
drug-induced cell death. They also indicate that cell membrane lipids are a plausible target
for antineoplastic therapy.
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Introduction
The plasma membrane is a biological structure made of hundreds of different lipids arranged
in two asymmetric leaflets and a plethora of proteins. It defines the boundary of every living
cell and its integrity is essential for life. Plasma membrane not only separates cell contents
from the external environment but also regulates what enters and exits the cell, contributes to
maintain cell shape and it is involved in different cellular processes such as polarity, adhesion,
invasion and motility. Moreover, it is also known that changes in cell membrane composition
and structure have important implications in many cancer processes [1]. The particularities of
the cell membrane of a malignant tumor cell may influence its ability to grow, attach and
respond to neighboring cells differently. It may also affect cancer cell motility, favoring tumor
invasion and metastasis.
Given that its integrity is required for survival, plasma membrane constitutes a sort of cellu-
lar Achilles heel, sensitive both to mechanical rupture and molecule-driven alterations. A break
in the integrity of the plasma membrane immediately compromises its essential role as a bar-
rier, resulting in the death of the affected cell. Not surprisingly, many organisms have devel-
oped pore-forming molecules designed to disturb membrane integrity for a variety of
purposes. Bacteria and other microorganisms (e.g. parasites) use them to wage war against
rival bacteria and to attack human cells [2–4]. Not to be overlooked, our immune cells also pro-
duce pore-forming molecules, such as the complement component C9, to attack bacteria and
protozoa, and perforin, a protein that kills virus-infected cells [5, 6].
Based on the differences that exist between cell membranes of malignant and normal cells,
diverse antitumor molecules were described as targeting this cell structure [1]. In this sense, we
have previously described the effects of elisidepsin (Irvalec1, PM02734), a synthetic cyclodep-
sipeptide closely related to the natural product Kahalalide F [7]. Elisidepsin rapidly inserts in
the plasma membrane, where it self-organizes and promotes lipid bilayer restructuration [8]. It
then induces a rapid loss of membrane integrity and necrotic cell death [8]. Although the
sequence of these biological events is well known, the target of elisidepsin at the cell membrane
was unnamed. Here, we identify glycosylceramides as the main target of elisidepsin in tumor
cell membranes. Moreover, we demonstrate that the absence of this lipid species render tumor
cells resistant to elisidepsin. In contrast, reactivation of glycosylceramide synthesis restores eli-
sidepsin sensitivity in the resistant cells. Altogether, these results indicate that glycosylcera-
mides act as elisidepsin targets, in order to trigger the membrane permeabilization that leads to
drug-induced cell death. They also suggest that tumor plasma membrane lipids are a valid tar-
get for anticancer treatment.
Materials and Methods
Reagents
Elisidepsin (C77H125F3N14O18, MW:1591.89) and its two derivatives, Oregon Green1
labelled elisidepsin (Irv-OG488) and Alexa Fluor1 555 labelled elisidepsin (Irv-A555), were
manufactured at PharmaMar SA. Syringomycin E was purified at PharmarMar. Sulforhoda-
mine B (SRB), Trizma1 base, Hoechst-33342, propidium iodide (PI), Dulbecco's modified
Eagle's medium (DMEM), McCoy’s medium, penicillin, streptomycin, fetal bovine serum
(FBS), thioflavine S, orcinol, sulphuric acid and chloroform HPLC grade were purchased from
Sigma (St. Louis, MO, USA). Methanol HPLC grade was from Carlo Erba (Val de Reuil,
France). D,L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and the
neutral glycosphingolipid mixture were fromMatreya (Pleasant Gap, PA, USA). C16-β-D-glu-
cosyl ceramide was from Avanti Polar Lipids (Alabaster, AL, USA). n-Butyldeoxynojyrimicin
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(NB-DNJ, Miglustat hydrochloride) was from Tocris Bioscience (Bristol, UK). Cytotoxic com-
pounds were purchased as follows: Amphotericin B, Edelfosine, Paclitaxel, Docetaxel, Epothi-
lone B, Vinorelbine, Vinblastine, Colchicine, Doxorubicin, Cisplatin, Mitomycin C,
5-fluorouracil (5-FU), Irinotecan, Etoposide and Methotrexate were from Sigma; Gemcitabine
was from Lilly (Indianapolis, IN, USA); Erlotinib was from Selleckchem (Houston,TX, USA).
Cell lines and cell culture
Colorectal carcinoma HCT-116 (CCL-247) cell line used in this study was purchased from the
American Type Culture Collection. The mouse melanoma cell line B16 (RCB0557) and the
mutant derivative GM95 (RCB1026) were purchased from the Riken Cell Bank (Ibaraki,
Japan). The elisidepsin resistant cell line HCT-116-Irv was developed in our laboratory from
the HCT-116cell line, using the classical stepwise selection method [9, 10]: the parental cells
were treated with increasing concentrations of elisidepsin and, at each stage, a stable surviving
population of cells was stablished before the next increment. The maximal elisidepsin concen-
tration used during the selection period was 100 μM and the overall process lasted 18 months.
HCT-116 and HCT-116-Irv were cultured in McCoy’s medium supplemented with 10% FBS, 2
mM glutamine and 100 U/ml penicillin and streptomycin at 37°C and 5% CO2. B16 and GM95
cells were maintained in DMEM with the same supplements and conditions.
Cell viability assays
Cells were seeded in 96-well microtiter plates and maintained at 37°C and 5% CO2 in drug-free
medium before treatment with vehicle alone or elisidepsin at the concentrations and times
indicated in the text. For cell survival quantification, a colorimetric assay using SRB was used
[11]. Briefly, after treatment, cells were washed twice with phosphate buffered saline (PBS),
fixed for 25 min in 1% glutaraldehyde solution, rinsed twice with PBS, stained in 0.4% SRB-1%
acetic acid solution for 30 min, rinsed several times with 1% acetic acid solution, and air-dried.
SRB was then extracted in 10 mM Trizma base solution, and the absorbance was measured at
490 nm in a microplate spectrophotometer. Results are expressed as percentage of control cell
survival and represent the mean of at least three independent experiments. IC50, half-maximal
inhibitory concentration, was used as a reference value.
Quantification of elisidepsin accumulation in tumor cells
HCT-116 cells were treated in triplicate with elisidepsin 7 μM in P6 culture plates at the times
indicated in the text. After treatment, cells were washed twice with cold PBS and scraped in the
same buffer. Cells were centrifuged and resuspended in 100 μL of methanol to extract the com-
pound bound to cells. Other plates were treated in the same conditions and the cells were col-
lected to determine the protein content in each case. The quantity of elisidepsin in each sample
was determined by HPLC-MS. The analysis consisted of gradient reversed phase chromatogra-
phy followed by positive ion electrospray tandem mass spectrometry (ESI/MS/MS) detection
using multiple reactions monitoring (MRM). The analytical column (Waters, YMC C18 3 μm,
50 x 2.1 mm) was placed in an oven at 50°C. The flow rate was 600 μL/min. The wash solvent 1
& 2 used was acetonitrile:2-propanol:methanol:water (1:1:1:1). Mobile phase A was water:for-
mic acid (500:0.5). Mobile phase B was acetonitrile:formic acid (500:0.5). The equipment used
was composed of a binary 10 AD vp HPLC (Shimadzu, Kyoto, Japan), a controller (Shimadzu),
an oven (Shimadzu), an autosampler (CTC PAL, Leap Technologies; Carrboro, NC, USA) and
a triple quadropole mass spectrometer (API4000, AB Sciex, Framingham, MA, USA). Data
were analyzed with Software Analyst version 1.5 with intelliquan quantitation tool (AB Sciex).
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Membrane permeabilization assays
Cells were seeded in P24 plates and cultured for 48 h as described above. Then, medium was
replaced with fresh culture medium (supplemented with 25 mMHEPES pH 7.4 and 50 μg/mL
PI) containing or not different concentrations of elisidepsin. Morphological changes and nuclei
staining in membrane permeabilized cells were followed by phase contrast and fluorescence
microscopy.
Electrophysiological recordings
The effects of elisidepsin on membrane conductance were analyzed in HCT-116 and HCT-
116-Irv cells as previously described [12–15]. Experiments were performed in a small bath
mounted on the stage of an inverted microscope (Nikon model TMS, Garden City, NY, USA)
continuously perfused with the extracellular solution (Tyrode-glucose buffer). Ion currents
were recorded at room temperature (20–22°C) using the whole-cell voltage-clamp configura-
tion of the patch-clamp technique [16] with an Axopatch 200B patch-clamp amplifier (Axon
Instruments, Foster City, CA). Currents were filtered at 2 kHz (four-pole Bessel filter), sampled
at 4 kHz. Data acquisition and command potentials were controlled by the CLAMPEX pro-
gram of PCLAMP 9.2 software (Axon Instruments). Micropipettes were pulled from borosili-
cate glass capillary tubes (Narishige, GD-1, Tokyo, Japan) on a programmable horizontal
puller (Sutter Instrument Co., San Rafael, CA, USA) and heat-polished with a microforge (Nar-
ishige). Pipette tip resistance averaged between 1 and 3 MO. The intracellular pipette solution
contained (in mM): K-aspartate 80, KCl 50, phosphocreatine 3, KH2PO4 10, MgATP 3,
HEPES-K 10, EGTA-K 5 and was adjusted to pH 7.25 with KOH. The external solution (Tyr-
ode-glucose buffer) contained (in mM): NaCl 130, KCl 4, CaCl2 1.8, MgCl2 1, HEPES-Na 10,
and glucose 10, and was adjusted to pH 7.40 with NaOH. Measurements were performed using
the CLAMPFIT program of PCLAMP 9.2.
FLIM-FRET-phasor approach
Two-photon fluorescence-lifetime imaging microscopy (FLIM) of live cells was carried out on
a MicroTime 200 system (PicoQuant, Germany) coupled with an Olympus IX71 inverted
microscope described in detail elsewhere [8]. In short, excitation at 755 nm was performed by a
mode-locked, femtosecond-pulsed Ti:Sapphire laser (Mai-Tai, Spectra Physics, CA). Two-
color fluorescence images were acquired simultaneously with two single-photon avalanche
diodes (SPAD, SPCM-AQR-14, Perkin Elmer, USA), through a dichroic beam splitter
FF560-Di01 and bandpass filters FF01-520/35 (Donor FRET channel: Irv-OG488), FF01-685/
40 (Acceptor FRET channel: Irv-A555) from Semrock, Germany. Acquisition time per pixel
accounted for 1.2–2 ms.
FLIM-FRET (Föster Resonance Energy Transfer) measurements: HCT-116 and HCT-
116-Irv cells were cultured in poly-L-lysine coated LabTek-II chambered coverglass slides
(Thermo Scientific-Nunc). The coating method consists in incubation of slides with poly-
L-Lysine 0.1 mg mL-1 in sterile PBS, overnight at 4°C, followed by three washes with PBS. After
48 h culture, cells were washed with Tyrode-glucose buffer and treated with a mix of FRET
donor (Irv-OG488) 200 nM, FRET acceptor (Irv-A555) 800 nM and elisidepsin 3 μM, keeping
DMSO lower than 0.5% v/v.
FLIM-FRET provides an intensity independent measurement of FRET. The fluorescence
lifetime is defined by the average time the fluorophore spends in the excited state, before to
return to the ground state, and it is characteristic of each fluorophore and its microenviron-
ment. Phasor analysis transforms the fluorescence lifetime data from each pixel into a coordi-
nate pair corresponding to the phase (F) and modulus (M) of a vector (phasor) [17], which is
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represented as a point with coordinates (s,g) in the phasor plot. In a reciprocal manner, each
point in the phasor plot can be mapped to a pixel of the FLIM image, facilitating the identifica-
tion of molecular species in a graphical way, avoiding fitting of multiexponential functions that
would require a large number of photons per pixel, which in general it is not possible to accu-
mulate in living cell measurements. Clusters of pixels with similar phasors in specific regions of
the phasor plot, selected by circular color cursors, are assigned to specific molecular species:
donor only, FRET and autofluorescence background.
When donor and acceptor molecules are at FRET distances (lower than 100 Å), the fluores-
cence lifetime of the donor would decrease from τD (donor unquenched) to τDA (donor
quenched by the presence of the acceptor) as a function of the FRET efficiency (E): τDA =
τD(1-E). FRET trajectories on the phasor plot are curved and they would represent realizations
of all possible donor phasors quenched by FRET with different efficiencies. FRET efficiencies
were estimated using the FRET calculator tool included in SimFCS program (Laboratory for
Fluorescence Dynamics, Irvine, CA), taking in account the contribution of donor only and
background lifetime species present in each pixel.
Cell lipids extraction and analysis
Lipid extracts from cells were obtained according to the Bligh and Dyer method with slight
modifications [18]. Briefly, a cell pellet was resuspended in 1 mL of distilled water, then 3.75
mL of chloroform:methanol (1:2) was added and the suspension was mixed by vortexing two
minutes; next, 1.25 mL of chloroform was added and vortexed one minute; last, 1.25 mL of
NaCl 1 M was added to the suspension and vortexed one minute. The suspension was centri-
fuged and the bottom organic phase was collected. This solution was dried under a nitrogen
stream and stored at -20°C. This extract was dissolved in a small volume of chloroform:metha-
nol (2:1) and lipids were separated in a HPTLC (high performance thin layer chromatography)
silica gel plate (Merck-Millipore, Darmstad, Germany) using a mobile phase of chloroform:
methanol (8:2). Lipids were visualized by staining the plate with thioflavine S (sprayed with
10 μg mL-1 in acetone:water (4:1) and visualized under UV light). Glycosylated lipids were
visualized by orcinol staining (sprayed with orcinol 0.5% in sulphuric acid 0.5 M and developed
with heat). Lipids were purified from thioflavine S stained plates by scratching the resin fol-
lowed by extraction with chloroform:methanol (2:1).
Interaction of elisidepsin with lipids
Interaction of purified lipid fractions with elisidepsin was evaluated with an overlay assay. Lip-
ids were applied onto a nitrocellulose membrane (Protran membrane, Whatman-GE, Piscat-
away, NJ, USA), blocked with non-fat milk 1% in PBS, and hybridized with a biotinilated
elisidepsin derivative or biotin as control (6 μM in blocking solution, 1 h at room temperature
with agitation). Elisidepsin-biotin interactions were detected by incubation with streptavidin-
HRP and subsequent chemiluminescence.
Overexpression of UGCG
GM95 cell line was transfected with an expression vector containing the GFP-tagged UGCG
human cDNA (Origene). For the transfection, Lipofectamine reagent (Life Technologies) was
used according the manufacturer’s protocol. Positive clones were selected with G-418 and by
fluorescence intensity.
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NMR analysis of purified lipids
A purified lipid fraction obtained from HCT-116 cell lipids was analyzed to determine its
NMR spectrum. 1H NMR was recorded on a Varian Unity 500 spectrometer (Palo Alto, CA,
USA) at 500 MHz. Chemical Shifts (δ) are reported in parts per millions (ppm) referenced to
CH3OH at 3.30 ppm.
Results
Characterization of elisidepsin resistance in HCT-116-Irv cells
HCT-116-Irv cells were derived from HCT-116 parental cells by a classical stepwise selection
procedure during 18 months. After this period, a pool of resistant cells with a very homogenous
behavior in all the analyzed variables was stablished and it was consider as a new cell line
named HCT-116-Irv. As shown in Fig 1A and Table 1, cells were 14.7-fold more resistant to
elisidepsin than parental HCT-116 cells. The IC50 values after 30 min exposure were 7.7
±4.1 μM and>100 μM μM for HCT-116 and HCT-116-Irv cells, respectively (Fig 1A). The
IC50 values after 72 h exposure were 5.5±0.8 μM and 81.5±0.8 μM for HCT-116 and HCT-
116-Irv cells, respectively (Fig 1A). To determine the stability of the acquired resistance in
HCT-116-Irv, cells were cultured for 15 passages in the absence of the drug and concentration-
response curves were performed in passage 2 and 15. The levels of resistance at both time
points were very similar, indicating that HCT-116-Irv cells had acquired a permanent resis-
tance to the drug (Fig 1B). HCT-116-Irv cell line did not show any cross resistance with other
common anticancer agents or other agents interacting with the cell membrane, indicating that
the resistance mechanism was specific for elisidepsin (Table 1). Additionally, we evaluated the
accumulation of the compound in both parental and resistant cells. Both cell lines were treated
with elisidepsin 7 μM at several time points, and the amount of drug retained in cells was quan-
tified by HPLC/MS. While the parental cells showed a rapid and large accumulation of elisidep-
sin, in the resistant cells the accumulation of the compound was remarkably smaller and
slower (Fig 1C).
Typical cell membrane perturbations caused by elisidepsin are not
observed in HCT-116-Irv cells
We have previously demonstrated that elisidepsin molecules localize in the cell membrane,
close enough to each other as to suggest that the compound could self-organize, forming supra-
molecular structures that likely trigger necrosis through the disruption of membrane integrity
[8]. We thus evaluated whether exposure to elisidepsin induced similar phenomena in HCT-
116-Irv cells. For this purpose, parental and elisidepsin-resistant cells were cultured in the pres-
ence of propidium iodide (PI) and exposed to the drug (10 μM) for 5 min. Cells were observed
by fluorescence microscopy. As shown in Fig 1D and S1 Movie, most of HCT-116 cells exhib-
ited a nuclear staining due to the uptake of PI. Simultaneously, cell morphology was seriously
altered with the formation of giant vesicles. All these effects were a consequence of the mem-
brane damage caused by elisidepsin. In contrast, no PI uptake or giant vesicle formation was
detected in the resistant cells (Fig 1D).
We finally analyzed the effect of the non-toxic concentration of elisidepsin 1 μM on mem-
brane conductivity in HCT-116 and HCT-116-Irv cells using a series of ramps from -100 mV
to +120 mV during 500 ms (Fig 1E). Right upper panel of Fig 1E shows the time course of the
elisidepsin effects on HCT-116 cells. As it is shown in the left upper panel, elisidepsin pro-
duced an increase of the membrane conductance at all membrane potentials (negative and
positive) that lead to the appearance of an inward and an outward current at negative and
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positive membrane potentials, respectively. The time constant indicated a fast process (107
±39 s; n = 4). The latency between the application of elisidepsin and the beginning of the
effects was 460±163 s (n = 4). The compound had virtually no effect in HCT-116-Irv cells
(Fig 1E, lower panels).
Fig 1. Characterization of the HCT-116-Irv resistance to elisidepsin. (A) Concentration-response curves showing the activity of elisidepsin after 30 min
and 72 h in HCT-116 (⬛) and HCT-116-Irv cells (⬜); results represent the mean±SD of at least three different experiments. (B) Stability of elisidepsin
resistance in HCT-116-Irv cells determined by concentration-response curves after 2 (⬛) and 15 (▲) culture passages in absence of the compound. HCT-
116 cells (●) are also depicted in the graph. Results represent the mean±SD of three different experiments. (C) Elisidepsin accumulation (pmol/mg protein) in
HCT-116 (white bars) and HCT-116-Irv cells (black bars). Both cell lines were treated with elisidepsin 7 μM at different time points and the accumulated
compound was quantified by HPLC/MS. Results represent the mean±SD of three different samples. Comparisons between different samples were analyzed
by Student’s t test. Differences were considered significant at *P<0.05, **P<0.01 and ***P<0.001. (D) Representative images of HCT-116 and HCT-116-Irv
cells exposed to elisidepsin 10 μM for 5 min. Phase contrast microscopy images showmorphological alterations and giant vesicles formation only in the wild-
type cells (white arrows). Fluorescence microscopy shows PI stained nuclei only in the parental cells. (E) Electrophysiological effects of elisidepsin 1 μM on
HCT-116 and HCT-116-Irv cells. Left panels show original records after applying a ramp pulse protocol from -100 mV to +120 mV during 500 ms. Right
panels show the amplitude of the maximum current at the end of the ramp together with the exponential fit of the process. HCT-116-Irv cells are completely
insensitive to the elisidepsin effects as shown in the current records. Holding potential was maintained at -80 mV.
doi:10.1371/journal.pone.0140782.g001
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Elisidepsin inserts differently in the cell membrane of sensitive and
resistant HCT-116 cells
We have used the FLIM-FRET (Fluorescence Lifetime Imaging-Föster Resonance Energy
Transfer) phasor approach to investigate whether elisidepsin inserts in a similar way into the
plasma membrane of HCT-116 and HCT-116-Irv cells. In this approach the fluorescence
decay from each pixel of the image is represented as a point in the phasor plot. This method
improves the Fast FLIM-FRET approach used in a previous work [8], and provides a simple
and quantitative graphical way of comparison of the two types of cells in terms of donor-
unquenched and donor-acceptor lifetimes and FRET efficiencies. Irv-OG488 (elisidepsin-Ore-
gon Green 488) and Irv-A555 (elisidepsin-Alexa Fluor 555) are respectively, the donor and the
acceptor molecules in the FRET assay.
Fig 2A shows the autofluorescence intensity image of representative untreated HCT-116
cells, measured in the donor channel, in the same experimental conditions as the FRET sam-
ples. Fig 2B shows the reciprocal selection of the grey autofluorescence cursors from the phasor
plot of the same cells, represented in Fig 2C.
Fig 2D shows the fluorescence intensity image of representative HCT-116-Irv cells treated
with 4 μM total elisidepsin (Irv-OG488 200 nM, Irv-A555 800 nM, elisidepsin 3 μM, 1:4:15).
We observe a low fluorescence signal in the media, with a fluorescent lifetime characteristic of
Irv-OG488 molecules, represented by the green mask and the green cursor respectively in the
FLIM-phasor image (Fig 2E), and the phasor plot (Fig 2F). This result indicates that most of
Table 1. Antiproliferative activity of elisidepsin and other compounds in HCT-116 and HCT-116-Irv
tumor cell lines.
Compound HCT-116 (IC50)
a HCT-116-Irv (IC50)
a RRb
Elisidepsin 5.5 x 10−6 M 8.1 x 10−5 M 14.7
Amphotericin B 5.2 x 10−6 M 6.1 x 10−6 M 1.2
Syringomycin E 2.0 x 10−5 M 1.5 x 10−5 M -1.4
Edelfosine 2.9 x 10−5 M 2.9 x 10−5 M 1.0
Paclitaxel 6.9 x 10−9 M 8.3 x 10−9 M 1.2
Docetaxel 2.9 x 10−9 M 1.8 x 10−9 M -1.6
Epothilone B 2.2 x 10−9 M 3.9 x 10−9 M 1.8
Vinorelbine 1.6 x 10−7 M 1.9 x 10−7 M 1.1
Vinblastine 3.2 x 10−10 M 4.1 x 10−10 M 1.3
Colchicine 3.9 x 10−9 M 2.8 x 10−9 M -1.4
Doxorubicin 1.4 x 10−7 M 9.9 x 10−8 M -1.4
Cisplatin 9.8 x 10−6 M 3.6 x 10−6 M -2.7
Mitomycin C 3.3 x 10−7 M 3.0 x 10−7 M -1.1
5-FU 4.0 x 10−6 M 1.1 x 10−5 M 2.8
Irinotecan 2.5 x 10−6 M 3.1 x 10−6 M 1.2
Gemcitabine 6.3 x 10−10 M 6.7 x 10−10 M 1.1
Etoposide 1.2 x 10−6 M 9.6 x 10−7 M -1.2
Methotrexate 3.7 x 10−8 M 7.7 x 10−8 M 2.1
Erlotinib 3.2 x 10−5 M 1.6 x 10−5 M -2.0
a IC50, cell growth half-maximal inhibitory concentration. Values represent the mean of three different
experiments.
b RR (resistance ratio): fold change between IC50 values from HCT-116-Irv and HCT-116
doi:10.1371/journal.pone.0140782.t001
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the Irv-OG488 molecules remained in the media, far from Irv-A555 molecules, and did not
interact with HCT-116-Irv cells. Inside the cell, there were not significant differences in the
autofluorescence of treated and untreated cells, showing grey color masks corresponding to
grey cursors in the phasor plot (Fig 2F).
Fig 2. Comparative interaction study of elisidepsin and the plasmamembrane of HCT-116 and HCT-116-Irv cells.Untreated HCT-116 cells:
Autofluorescence intensity image (A), FLIM-phasor image (B) and the corresponding phasor plot (C) of representative untreated HCT-116 cells. Grey mask on
the FLIM-phasor image, and grey circles on phasor plot correspond to autofluorescence phasors. HCT-116-Irv cells treated with 5μM total elisidepsin (FRET
donor: Irv-OG488 200 nM, FRET acceptor: Irv-A555 800 nM, elisidepsin 3 μM, 1:4:15): Fluorescence intensity image (D), FLIM-phasor image (E), and the
corresponding phasor plot (F) of representative elisidepsin treated HCT-116-Irv cells. Green mask on FLIM-phasor image and green circles on phasor plot
correspond to FRET donor (Irv-OG488) molecular species outside the cell where donor and acceptor molecules are at distances longer than 70 Å. For these
species, the lifetime of Irv-OG488 in the media is not affected by the presence of Irv-A555 molecules, and it was assigned to the donor-only (τD, donor
unquenched) phasor in the phasor plot for FLIM-FRET-phasor analysis. The lifetimes inside the cells have not changed substantially with respect to untreated
cells, showing the typical autofluorescence behavior (grey mask and cursor). Elisidepsin molecules were not detected inside HCT-116-Irv treated cells. HCT-
116 cells treated with 4μM total elisidepsin (FRET donor: Irv-OG488 200 nM, FRET acceptor: Irv-A555 800 nM, elisidepsin 3 μM, 1:4:15): Fluorescence
intensity image (G), FLIM-phasor image (H), and the corresponding phasor plot (I) of representative elisidepsin treated HCT-116 cells. Green mask on FLIM-
phasor image and green circles on phasor plot correspond to Irv-OG488molecular species inside the cell that are not complexed with other elisidepsin
molecules, so do not change their lifetime (donor unquenched lifetime). Pink mask and pink cursor correspond to elisidepsin complexes, containing
elisidepsin, Irv-OG488 and Irv-A555 molecules at distances shorter than 50 Å, mainly located in the plasmamembrane of affected cells. The lifetime of the
FRET donor (Irv-OG488) in these complexes (τDA) decreases due to FRET to neighboring FRET acceptor (Irv-A555) molecules, and their corresponding
phasor fall in the quenching FRET trajectory. Excitation wavelength: 755 nm. Laser frequency (f): 80x106 s-1. Emission: FF01 520/35. Phasor plot: g and s axis
represent the real and imaginary parts of the Fourier transform of the fluorescence impulse response I(t): gðoÞ ¼
Z 1
0
IðtÞ  cos ot  dt ¼ M  cos ;
sðoÞ ¼
Z 1
0
IðtÞ  sin ot  dt ¼ M  sin ;ω = 2 π f; M and ϕ are respectively the modulus and the phase of the phasor.
doi:10.1371/journal.pone.0140782.g002
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Fig 2G shows the fluorescence intensity image of representative HCT-116 cells treated with
4 μM total elisidepsin (Irv-OG488 200 nM, Irv-A555 800 nM, elisidepsin 3 μM, 1:4:15). We
observe an important increase in the fluorescence intensity of Irv-OG488 localized mainly in
the plasma membrane. The FLIM-phasor image (Fig 2H) shows Irv-OG488 molecules in the
plasma membrane and inside HCT-116 affected cells (green mask), with a fluorescence lifetime
characteristic of Irv-OG488 (green cursor in the phasor plot; Fig 2I). In addition, we have
detected a new Irv-OG488 molecular species in specific regions of the plasma membrane of
HCT-116 treated cells, with a fluorescence lifetime shorter than measured for Irv-OG488 (pink
cursor in the phasor plot; Fig 2I). The decrease in the fluorescence lifetime is indicative of a
FRET process between the FRET donor (Irv-OG488) to the FRET acceptor (Irv-A555) mole-
cules. The distribution of Irv-OG488, Irv-A555, and elisidepsin molecules in the membrane eli-
sidepsin assemblies proves to be non-random. Regions with shorter lifetime would correspond
to [elisidepsin]n assemblies in the plasma membrane, containing Irv-OG488 and Irv-A555
molecules at FRET distances (*60% FRET efficiency), while membrane regions with high Irv-
OG488 intensity and unquenched lifetime would correspond to [elisidepsin]n which do not
contain Irv-A555 molecules, or containing Irv-OG488 and Irv-A555 molecules far from FRET
distances (>100 Å).
In previous FRET studies, using the same fluorescent elisidepsin analogs, we have observed
that, when a mix of Irv-OG488 and elisidepsin molecules interacted with the cell membrane of
A549 cells, they changed their conformation, forming some kind of assembly in the membrane
so that the fluorescence signal per membrane pixel increases several orders of magnitude, com-
pared to the fluorescence detected from Irv-OG488 molecules in solution [8].
These results demonstrated that like A549 cells, at cytotoxic concentrations, elisidepsin mol-
ecules are forming some kind of assemblies all throughout the plasma membrane of HCT-116
cells, former to the disruption of membrane integrity. These elisidepsin assemblies were not
observed in elisidepsin treated HCT-116-Irv cells.
Elisidepsin interacts with glycosylated ceramides in the plasma cell
membrane
Since HCT-116-Irv resistant cells accumulated less elisidepsin and the compound was detected
at lower levels in their cell membrane, we investigated whether this was due to an altered lipid
composition. To this end, we extracted total lipids from HCT-116 and HCT-116-Irv cell pellets
using standard methods based on chloroform and methanol combinations. Lipid extracts were
then fractionated by HPTLC (high performance thin layer chromatography) and the plates
were stained with specific dyes for lipids (Fig 3A). Interestingly, we identified two subfractions
in HCT-116 cells that were almost absent in their resistant counterpart (white arrows 1 and 4
in Fig 3A). Staining HPTLC plates with orcinol, a classic sugar staining method, demonstrated
that the two differential lipid species identified contained glycosylated lipids (Fig 3B).
To determine if elisidepsin was interacting specifically with any of the lipid fractions
detected in both cell lines, an overlay assay was carried out. The pattern of the total lipid extract
was divided in 8 fractions that were collected from a monodimensional HPTLC and named
from “a” to “h” (Fig 3A). These lipid fractions were applied on a nitrocellulose membrane and
were incubated with an elisidepsin-biotin derivative that facilitated its subsequent detection
(Fig 3C). The fraction which contained the differential subfractions identified in the previous
experiment, and now called “e”, was positive for the binding to elisidepsin-biotin. This binding
occurred only in the extract from the HCT-116 cells. There was no positive signal in the resis-
tant cells extract.
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Fig 3. Glycosylceramides pattern and elisidepsin interaction with glycosylceramides in HCT-116 and HCT-116-Irv cells. (A) Monodimensional silica-
gel HPTLC of the lipid extract from HCT-116 and HCT-116-Irv. The plate was stained with thioflavine S. Arrows show a group of nearby fractions with
different presence in both cell lines. The total extract was divided in 8 fractions (a to h) that were purified for subsequent experiments. (B) Glycolipid detection
in lipid extracts from HCT-116 and HCT-116-Irv. Total lipid extracts from HCT-116 and HCT-116-Irv were developed on HPTLC silica plates and visualized
with orcinol-sulphuric acid staining to reveal the presence of glycosylated lipids. Control samples were added to confirm the results; left panel: control HPTLC
incubated with sulphuric acid alone; right panel: HPTLC stained with orcinol-sulphuric acid. The samples were: 1, HCT-116-Irv lipid extract (200 μg); 2, HCT-
116 lipid extract (200 μg); 3, neutral glycosphingolipid mixture (cerebrosides, lactosylceramides, ceramide trihexosides, globosides –Gb4-) (10 μg); 4, C16-β-
D-glucosyl ceramide (6 μg); 5, glucose (5 μg). The lipid fractions that are related to elisidepsin binding or resistance are pointed out inside the dot line square.
(C) Dot-blot assay for the interaction of biotin or elisidepsin-biotin with the lipid fractions from the wt and the resistant cells. Arrows indicate the fraction with
specific binding to elisidepsin-biotin only present in HCT-116 cells. (D) Dot-blot assay for the interaction of biotin or elisidepsin-biotin with the selected lipid
fractions from the parental and the resistant cells. Fraction 4 from HCT-116 is the only fraction that interacts with elisidepsin-biotin. (E) Competitive binding
assay with elisidepsin. Nitrocellulose membranes with spots of the lipid fraction 4 from HCT-116 were incubated with different proportions of elisidepsin-biotin
and elisidepsin (1:1, left; 1:15, right). A lower signal was detected when elisidepsin quantity was increased. (F) NMR analysis of a purified lipid fraction of
HCT-116 cells. NMR spectra from C16-β-D-glucosyl ceramide and purified F4 lipid fraction from HCT-116 are shown. Letters and arrows indicate the
assignation of signals from F4 spectra in a model glycosylceramide molecule.
doi:10.1371/journal.pone.0140782.g003
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Next, we investigated which of the previously identified differential subfractions was neces-
sary for the binding to elisidepsin-biotin. For this purpose, we performed two preparative
HPTLC applying 10 mg of the lipid extracts from each cell line, and the 4 fractions depicted in
“e” in Fig 3A were purified separately. Each individual subfraction was assayed again through
an overlay assay with elisidepsin-biotin. As seen in Fig 3D, fraction number 4 was identified as
the only responsible for the binding to elisidepsin-biotin in parental HCT-116 cells. A competi-
tion assay between elisidepsin-biotin and elisidepsin (Fig 3E) showed that elisidepsin could dis-
place the biotinylated compound, indicating the specificity of the binding. An NMR (nuclear
magnetic resonance) study of the purified lipid fraction number 4 revealed similarities with a
commercial C16-β-D-glucosyl ceramide (Fig 3F).
Glycosylceramide levels determine the sensitivity of tumor cells to
elisidepsin
We assessed if glycosylceramides were needed for elisidepsin-induced disruption of the plasma
membrane and necrosis. For this purpose we used the mouse melanoma B16 cell line and its
mutant derivative GM95, described to lack UDP-glucose:ceramide glucosyltransferase
(UGCG; EC 2.4.1.80) activity [19]. HPTLC analysis of lipid extracts from both cell lines con-
firmed the absence in GM95 cells of lipids in the region of the identified glycosylceramides (Fig
4A and 4B). B16 cells were sensitive to elisidepsin, displaying the typical membrane permeabi-
lization and formation of large vesicles observed in other tumor cell lines (Fig 4C and 4D;
Table 2). In contrast, UGCG-deficient GM95 cells were resistant to elisidepsin (Fig 4C and
Table 2) showing a behavior similar to that of HCT-116-Irv cells (Fig 4D). Interestingly, over-
expression of UGCG gene in GM95 cells (GM95-UGCG cells) rendered them sensitive to elisi-
depsin, at a similar level of that of B16 cells (mean IC50 values of 9.0 and 6.9 μM, respectively;
Fig 4C). Furthermore, as observed in Fig 4D and S2 Movie, GM95-UGCG showed typical elisi-
depsin-induced morphological changes and membrane permeabilization by contrast phase or
fluorescence microscopy. Similarly, an increase in cell resistance was observed in HCT-116
parental cells after pretreatment with the UGCG inhibitors D,L-threo-1-Phenyl-2-decanoyla-
mino-3-morpholino-1-propanol (PDMP) and n-Butyldeoxynojyrimicin (NB-DNJ, Miglustat
hydrochloride) (Fig 5).
Discussion
In this manuscript, we describe a major role of glycosylceramides in the antitumor effects of eli-
sidepsin. Our results show that elisidepsin specifically interacts with glycosylceramides
extracted from human colon carcinoma HCT-116 cells. This lipid fraction was almost absent
in an elisidepsin-resistant cell line (HCT-116-Irv). Furthermore, GM95, an UGCG deficient
cell line derived from the mouse melanoma B16 cells, was also resistant to elisidepsin. Over-
expression of the UGCG gene in these cells reactivated the synthesis of glycosylceramides, ren-
dering them sensitive to elisidepsin at levels comparable to those observed in the parental,
UCGC expressing cell line. Altogether, these results indicate that glycosylceramides act as
membrane targets of elisidepsin, in order to trigger the membrane permeabilization that leads
to drug-induced cell death. These results are not surprising. Given that elisidepsin directly tar-
gets the plasma membrane of tumor cells, it was likely that the mechanism of acquired resis-
tance would be related to changes in cell membrane composition. The results exposed here
show that, in fact, resistance is principally due to deficiencies in glycosylceramides levels.
For several decades, anticancer drug discovery has been dominated by the idea that proteins
were the only differential targets in the cell membrane, whereas lipids were regarded as passive
components. Nevertheless, cell membrane lipids have been described as targets for different
Interaction of Elisidepsin with Glycosylceramides
PLOS ONE | DOI:10.1371/journal.pone.0140782 October 16, 2015 12 / 18
molecules from varied origin [20–22]. For example, direct interaction between amphotericin B
and ergosterol is required for the killing of yeast cells [20]. Similarly, the wide group of defensin
peptides include members that bind specifically to phosphoinositides or to glucosylceramides
in the cell membrane and induce cell lysis in fungal and tumor cells [23–25]. Our results show
that a similar situation happens with elisidepsin in tumor cells, since the presence of
Fig 4. Activity of elisidepsin in B16, GM95 and GM95-UGCG cell lines. (A) HPTLC analysis of the total lipid extracts from the three cell lines. Lipids were
separated in chloroform:methanol (8:2) and stained with thioflavine S. (B) Orcinol staining of glycolipids present in the lipid extracts from the three cell lines.
Lipids were separated as mentioned before. In the last lane, C16-β-D-glucosyl ceramide was included as control. In (A) and (B): 1, lipid extract from B16
(200 μg); 2, lipid extract from GM95 (200 μg); 3, lipid extract from GM95-UGCG (200 μg); 4, C16-β-D-glucosyl ceramide (6 μg). Arrows indicate the lipid
fractions that are present or completely absent in the cell lines (C) Concentration-response curves for elisidepsin obtained after 72 h treatment in B16 (▲),
GM95 (⬛) and GM95-UGCG cells (⬜); results represent the mean±SD of at least three different experiments. (D) Representative images of B16, GM95 and
GM95-UGCG cells exposed to different concentrations of elisidepsin (10, 25 and 50 μM) for 5 min. Phase contrast microscopy images showmorphological
alterations and giant vesicles formation only in B16 and GM95-UGCG cells (white arrows). PI stained nuclei are shown in the fluorescence microscopy
images from both cell lines. GM95 cells do not show any response to the treatment with elisidepsin.
doi:10.1371/journal.pone.0140782.g004
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glycosylceramides in the cell membrane is necessary for the cytolytic activity of the compound.
Indeed, in HCT-116 parental cells which have detectable levels of glycosylceramides, the accu-
mulation of elisidepsin in the cell membrane is very fast. This coincides with the alteration of
cell morphology and physiology, the disruption of membrane integrity and the induction of
necrotic cell death. Finally, FRET analysis confirmed that elisidepsin molecules are forming
some kind of assemblies throughout the plasma membrane of HCT-116 cells, an effect that
precedes the disruption of membrane integrity. These findings are in agreement with previous
ones showing that elisidepsin rapidly and irreversibly targets the plasma membrane in breast
cancer (SKBR-3, MCF-7 and MDA-MB-453), skin (A431) and cervix (HeLa) tumor cell lines
[8, 26, 27]. In contrast, HCT-116-Irv cells have reduced levels of glycosylceramides and thus a
reduced accumulation of elisidepsin, even after prolonged exposures. Furthermore, elisidepsin
cannot be observed in the plasma membrane of these resistant cells. Consequently, we do not
detect any change in membrane conductance or permeability and drug treatment did not
induce the characteristic necrotic cell death. Moreover, when comparing the sensitivity of
Table 2. Antiproliferative activity of elisidepsin and other compounds in B16 and GM95 tumor cell
lines.
Compound B16 (IC50)
a GM95 (IC50)
a RRb
Elisidepsin 7.9 x 10−6 M 7.0 x 10–5 M 8.9
Syringomycin E 1.1 x 10−5 M 9.0 x 10−6 M -1.3
Gemcitabine 5.6 x 10−9 M 8.1 x 10−9 M 1.4
Mitomycin C 5.7 x 10−6 M 2.5 x 10−6 M -2.3
Paclitaxel 1.5 x 10−8 M 3.4 x 10−8 M 2.2
Cisplatin 1.8 x 10−5 M 9.4 x 10−6 M -2.0
Doxorubicin 1.8 x 10−7 M 9.4 x 10−8 M -1.9
Irinotecan 9.5 x 10−5 M 4.5 x 10−5 M -2.1
Methotrexate 5.0 x 10−7 M 3.7 x 10−7 M -1.4
a IC50, cell growth half-maximal inhibitory concentration. Values represent the mean of three different
experiments.
b RR: fold change between IC50 values from GM95 and B16
doi:10.1371/journal.pone.0140782.t002
Fig 5. Effect of glucosylceramide synthase inhibitors, PDMP andNB-DNJ on the antiproliferative
activity of elisidepsin. (A) Concentration-response curves of elisidepsin (30 min incubation) in HCT-116
cells pretreated for 72 h with the glucosylceramide synthase inhibitor PDMP 10 μM (⬜) or vehicle (⬛); (B)
Concentration-response curves of elisidepsin (30 min incubation) in HCT-116 cells pretreated for 48 h with
the glucosylceramide synthase inhibitorNB-DNJ 200 μM (⬜) or vehicle (⬛). Results represent the mean±SD
of three different experiments.
doi:10.1371/journal.pone.0140782.g005
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HCT-116-Irv cells to other commonly used anticancer drugs, no significant cross-resistance
was observed, independently of their mechanisms of action. This lack of cross-resistance
against other chemotherapeutics not only reflects the specificity of the resistance developed by
these cells against elisidepsin, but also confirms that elisidepsin has a mode of action different
from other common anticancer compounds. Altogether, these results validate the hypothesis
of glycosylceramides as the cell membrane target of elisidepsin.
Glycosylceramides are important metabolic intermediates which serve as the starting point
in the biosynthesis of a wide variety of glycosphingolipids [28, 29]. In a first glycosylation,
UGCG or UDP-galactose:ceramide galactosyltransferase (CGT; EC 2.4.2.62) transfer glucose
or galactose from UDP-glucose or UDP-galactose to the 1-hydroxyl group of ceramide, yield-
ing glucosylceramide or galactosylceramide, respectively [28]. From these, more complex gly-
cosylsphingolipids, such as lactosylceramide, globotriaosylceramide, monosialoganglioside and
others can be synthesized by incorporation of additional sugar residues by different glycosyl-
transferases [30]. Besides their essential roles as structural components of the cell membrane,
these lipids are known to participate in vital cellular processes such as signal transduction, dif-
ferentiation, migration, apoptosis, proliferation, senescence, and inflammation [31]. Moreover,
they are widely described as binding sites for bacteria, viruses and toxins [22, 32, 33]. Glycosyl-
ceramides, as well as other glycosphingolipids, have also been intensively studied in regard to
their role in tumor pathology [34]. In tumor cells, they have many different functions related
to tumorigenesis, cancer progression and drug resistance [35–37]. For this reason, the manipu-
lation of sphingolipid metabolism is currently being studied as a novel and promising strategy
for cancer therapy [38–40].
Of note, levels of glycosylceramides and other glycosphingolipids as well as enzymes
involved in their metabolism are increased in cancer cells [34, 41]. It has been found that
increased expression of UGCG is correlated to the progression of breast cancer, renal cancer,
ovarian cancer and leukemia and is frequently correlated with MDR1 levels in tumor samples
[42–46]. On the other hand, high mRNA expression of ceramide galactosyltransferase is related
to increasing risk of metastases in prostate or breast tumors [47, 48]. Moreover, galactocera-
mide levels can be used as a molecular marker in human oligodendrogliomas and astrocytomas
[49]. Transcriptional repression of the galactocerebrosidase (GALC; EC 3.2.1.46) gene was
reported in patients with head and neck squamous cell carcinoma [50]. These reported differ-
ences in membrane composition of cancer cells could be extremely important for the activity
of elisidepsin since our results show that levels of glycosylceramides determine the response to
elisidepsin in tumor cells. Whether analysis of glycosylceramide levels or enzymes involved in
its metabolism could be potentially used to select patients that would benefit from elisidepsin
therapy remains to be confirmed.
In summary, to exert its antitumor activity, elisidepsin binds to glycosylceramides in the cell
membrane. The lack of these lipid species in the plasma membrane confers specific resistance
to the drug through lower accumulation on it and thus, to the absence of the biological effects
that are normally induced by drug treatment (e.g., changes in membrane conductance, changes
in membrane permeability and necrotic cell death). These results highlight the importance of
lipid composition and membrane conformation for the sensitivity to elisidepsin. They also
indicate that cell membrane lipids are a plausible target for antineoplastic therapy.
Supporting Information
S1 Movie. Plasma membrane permeabilization induced by elisidepsin in HCT-116 cells.
Representative sequence of images from HCT-116 and HCT-116-Irv cells exposed to elisidep-
sin 10 μM for 5 min. In the presence of propidium iodide, undamaged cells show intact nuclei
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while permeabilized cells show PI stained nuclei.
(AVI)
S2 Movie. Plasma membrane permeabilization induced by elisidepsin in GM95-UGCG
cells. Representative sequence of images from GM95 and GM95-UGCG cells exposed to elisi-
depsin 20 μM for 5 min. In the presence of propidium iodide, undamaged cells show intact
nuclei while permeabilized cells show PI stained nuclei.
(AVI)
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